← Leaderboards
Paris Margaritis
Geneventiv Therapeutics, Inc.
$2,542,236
Attributed
$2,542,236
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2024–25$2M$1.5M$1M$500K$0
'24
'25
Funding mix
By agency
NIH$2,542,236 · 1
By mechanism
R44$2,542,236 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Hemophilia B”
- Christian Kastrup · Versiti Wisconsin, Inc.$2,182,730
- Moanaro Biswas · Indiana University Indianapolis$882,612
- Seema Rajnikant Patel · Emory University$705,303
- Charles H Askew · Nabgen, Inc.$496,933
- Miguel Escobar · University Of Texas Rio Grande Valley$453,070
- John Fraser Wright · Stanford University$447,530
Research focus
Hemophilia BInheritedHalf-LifeHemophilia AHemorrhageInfusion ProceduresGenerationsGene TherapyAntibodiesCofactorFactor XBlood Coagulation DisordersDesignDoseCanine ModelFactor XaEnzyme Replacement TherapyBlood Coagulation FactorCoagulation ProcessF8 GeneFactor IxFactor IxaCommercializationInhibitor
Grant awards (3)
Development of a universal gene therapy for hemophilia A or B with or without inhibitors$1,266,694
R44 · FY2025 · HL · contact PI
Development of a universal gene therapy for hemophilia A or B with or without inhibitors$45,344
R44 · FY2025 · HL · contact PI
Development of a universal gene therapy for hemophilia A or B with or without inhibitors$1,230,198
R44 · FY2024 · HL · contact PI